Objective-The mature form of human vascular endothelial growth factor-D (hVEGF-D ⌬N⌬C ) is an efficient angiogenic factor, but its full mechanism of action has remained unclear. We studied the effects of hVEGF-D ⌬N⌬C in endothelial cells using gene array, signaling, cell culture, and in vivo gene transfer techniques. Methods and Results-Concomitant with the angiogenic and proliferative responses, hVEGF-D ⌬N⌬C enhanced the phosphorylation of VEGF receptor-2, Akt, and endothelial nitric oxide synthase. Gene arrays, quantitative reverse transcription-polymerase chain reaction, and Western blot revealed increases in VEGF-A, stanniocalcin-1 (STC1), and neuropilin (NRP) 2 expression by hVEGF-D ⌬N⌬C stimulation, whereas induction with hVEGF-A 165 altered the expression of STC1 and NRP1, another coreceptor for VEGFs. The effects of hVEGF-D ⌬N⌬C were seen only under high-serum conditions, whereas for hVEGF-A 165 , the strongest response was observed under low-serum conditions. The hVEGF-D ⌬N⌬C -induced upregulation of STC1 and NRP2 was also evident in vivo in mouse skeletal muscle treated with hVEGF-D ⌬N⌬C by adenoviral gene delivery. The importance of NRP2 in hVEGF-D ⌬N⌬C signaling was further studied with NRP2 small interfering RNA and NRP antagonist, which were able to block hVEGF-D ⌬N⌬C -induced survival of endothelial cells.
T herapeutic angiogenesis is a potential tool for the treatment of cardiovascular diseases. Delivery of angiogenic factors can be used to stimulate the formation of new capillaries and collateral vessels in ischemic myocardium and lower limbs. By this method, it may be possible to increase blood perfusion in ischemic muscles, especially in those patients for whom conventional revascularization strategies, such as angioplasty and bypass surgery, are not suitable. 1, 2 Vascular endothelial growth factors (VEGFs) are effective compounds for therapeutic angiogenesis. They are dimeric glycoproteins that regulate endothelial cell behavior, angiogenesis, and lymphangiogenesis. The VEGF family contains at least 6 members: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placental growth factor. Their signaling is mediated primarily via 3 tyrosine kinase receptors: VEGF receptor (VEGFR)-1 (Flt-1), VEGFR-2 (Flk-1/KDR), and VEGFR-3 (Flt-4). In addition, 2 coreceptors for VEGFs, neuropilin (NRP)-1 and NRP2, have been identified. [1] [2] [3] [4] A novel member of the VEGF family, VEGF-D, was initially described as a c-fos-induced growth factor. 5, 6 It is synthesized as a large precursor protein that is proteolytically processed by plasmin and some other serine proteases to release the C-and N-terminal peptides. The precursor form of VEGF-D binds to and preferentially activates VEGFR-3, but after proteolytic cleavage, the binding affinity to the VEGFR-2 is increased many fold. 6 -9 Unlike VEGF-A, VEGF-D is not regulated by hypoxia, but regulation by cell-to-cell contacts mediated by cadherin-11 has been reported in fibroblasts. 10 Orphan receptors hepatocyte nuclear factor-4␣ and chicken ovalbumin upstream promoter transcription factor may also play a role in VEGF-D regulation. 11 In adult human tissues, VEGF-D is produced mainly in heart, lung, skeletal muscle, colon, and small intestine, 4 and its expression in cancer may have some prognostic value. 5, 12 Mature proteolytically processed form of human VEGF-D (hVEGF-D ⌬N⌬C ) has been shown to be an effective tool in vivo, inducing capillary enlargement and vascular permeability with an efficiency similar to that of hVEGF-A 165 . [13] [14] [15] This is probably due to the binding of hVEGF-D ⌬N⌬C to VEGFR-2, the main receptor mediating angiogenic effects of VEGFs. 3, 4 However, because of the relatively low efficiency of recombinant hVEGF-D ⌬N⌬C to activate VEGFR-2 in cell cultures 16 the mechanism of action has remained unclear. In particular, target genes and signaling mechanisms of hVEGF-D ⌬N⌬C in endothelial cells remain poorly understood. The aim of this study was to compare the angiogenic and proliferative effects of hVEGF-D ⌬N⌬C and hVEGF-A 165 in endothelial cells and to find novel target genes for hVEGF-D ⌬N⌬C by using gene array, signaling, and cell culture techniques. Findings from gene expression studies done with human umbilical vein endothelial cells (HUVECs) were confirmed in mouse hindlimb skeletal muscles treated with hVEGF-D ⌬N⌬C by adenoviral (Ad) gene delivery.
Materials and Methods
Angiogenic and proliferative effects of hVEGF-D ⌬N⌬C in vitro were studied with tube formation assay, MTS assay (Promega), and [ 3 H]thymidine incorporation assay. Secretion of hVEGF-D ⌬N⌬C protein from AdhVEGF-D ⌬N⌬C and AdCMV control virus-transduced HUVECs was analyzed by VEGF-D ELISA and Western blot. Total RNA was extracted from samples collected 36 and 72 hours posttransduction, and probes were hybridized to Affymetrix Human Genome U133 Plus 2.0 GeneChips. Data analysis was performed using dCHIP1.3 software. Changes in the gene expression levels were confirmed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and Western blot. For in vivo confirmations, hindlimb skeletal muscles (m. caput gastrocnemius) of LDLR Ϫ/Ϫ ApoB 100/100 mice were transduced with AdhVEGF-D ⌬N⌬C and AdCMV control virus as previously described. 15 For more details, please see the supplemental materials, available online at http://atvb.ahajournals.org.
Results

Angiogenic and Proliferative Effects of hVEGF-D ⌬N⌬C In Vitro
To study the angiogenic effects of hVEGF-D ⌬N⌬C and hVEGF-A 165 in vitro, telomerase-immortalized microvascular endothelial cells were cultured on collagen gel in the presence of different concentrations of recombinant human (rh) VEGF-D ⌬N⌬C or rhVEGF-A 165 . As shown in Figure 1A , a clear induction of tubule formation was achieved with rhVEGF-A 165 (50 ng/mL), whereas a higher concentration of rhVEGF-D ⌬N⌬C (250 ng/mL) was needed to stimulate the angiogenic responses. In HUVECs, rhVEGF-D ⌬N⌬C was able to induce phosphorylation of VEGFR-2, Akt, and endothelial nitric oxide synthase (eNOS) ( Figure 1B ). However, a concentration 10ϫ as high of rhVEGF-D ⌬N⌬C (500 ng/mL) was needed to achieve the same activation of VEGFR-2 as with 50 ng/mL rhVEGF-A 165 ( Figure 1B ). For cell survival assays, HUVECs stimulated with rhVEGF-A 165 (50 ng/mL) or varying concentrations of rhVEGF-D ⌬N⌬C were either kept under serum-free conditions for 48 hours or restimulated after 24 hours under high-serum conditions for an additional 24 hours. As seen in Figure 1C , only a weak stimulation of HUVECs was achieved with rhVEGF-D ⌬N⌬C under low-serum conditions, whereas under high-serum conditions, the level of stimulation for rhVEGF-D ⌬N⌬C was significantly higher (PϽ0.005). On the other hand, cellular survival of rhVEGF-A 165 -induced HUVECs was at the same level in both conditions ( Figure 1C ). Thus, these in vitro studies indicate that rhVEGF-D ⌬N⌬C has the capacity to stimulate angiogenic responses, as well as survival of HUVECs, but high-serum conditions and higher concentration of growth factor are needed to achieve the same activation of endothelial cells as with rhVEGF-A 165 . From the VEGF growth factor family, rhVEGF-C is most closely related to rhVEGF-D ⌬N⌬C by its structure and receptor-binding capacity. The ability of rhVEGF-C to induce HUVECs survival under high-serum conditions was very similar to that of rhVEGF-D ⌬N⌬C (Sup- plemental Figure I ). In HUVECs, VEGFR-2 expression level is 10-times higher than that of VEGFR-3 (data not shown), thus, the effects of hVEGF-D ⌬N⌬C has most probably been mediated via VEGFR-2.
To further study the effects of hVEGF-D ⌬N⌬C in vitro, adenoviral gene delivery (Ad) with AdhVEGF-D ⌬N⌬C and AdCMV control virus was performed. Significant expression of hVEGF-D ⌬N⌬C mRNA was seen in AdhVEGF-D ⌬N⌬Ctransduced HUVECs 6 hours posttransduction (data not shown) and hVEGF-D ⌬N⌬C protein secretion to the cell culture medium as soon as 12 hours posttransduction ( Figure  2A ). Only a minor increase in hVEGF-D ⌬N⌬C secretion was noticed after 72 hours (Figure 2A ). Transduction with AdhVEGF-D ⌬N⌬C for up to 72 hours did not alter cell viability assessed by Annexin V staining (Supplemental Figure II) . The correct size of hVEGF-D ⌬N⌬C protein produced by AdhVEGF-D ⌬N⌬C -transduced HUVECs was confirmed with Western blot ( Figure 2B ), and its ability to bind and activate VEGFR-2 was tested with a BaF3-R2 viability assay (Supplemental Figure III) . No hVEGF-D ⌬N⌬C mRNA or protein production was observed in AdCMV-transduced control cells (data not shown and Figure 2B ). The conditioned medium collected from AdCMV-transduced HUVECs was not able to stimulate VEGFR-2-expressing Ba/F3 cells (Supplemental Figure III ). In addition, increased phosphorylation of VEGFR-2 downstream signaling factor eNOS was noticed 36 hours posttransduction in AdhVEGF-D ⌬N⌬C -treated HUVECs in comparison with the AdCMV-transduced control cells ( Figure 2B ). In AdhVEGF-D ⌬N⌬C -transduced wells, a rearrangement of the HUVECs into tubule-like structures closely resembling small capillaries was seen 72 hours after gene delivery ( Figure 2C 
Gene Expression Study With hVEGF-D ⌬N⌬C
To clarify the target genes of hVEGF-D ⌬N⌬C in endothelial cells, we performed gene expression analysis with Affymetrix Human Genome U133 Plus 2.0 GeneChips. HUVECs treated with AdhVEGF-D ⌬N⌬C and AdCMV control virus under high-serum conditions were harvested 36 and 72 hours posttransduction. Data analysis was performed using dCHIP1.3 software. The criteria for the genes to be further analyzed were as follows: up-or downregulation by 1.5-fold (PϽ0.05) and false discovery rate 0%. With these criteria, the expression of 673 genes was significantly altered at 36 hours (219 upregulated and 454 downregulated), and at 72 hours the expression of 256 genes was altered (148 upregulated and 108 downregulated). The most important gene clusters found from the data are presented in Supplemental Table III . Briefly, VEGFR-2 downstream signaling factors together with angiogenesis-related growth factors and NRP2 were mostly upregulated at the 36-hour time point, whereas intercellular junction proteins were downregulated at both time points. In addition, the expression of several extracellular matrix-related genes, such as collagen type V␣1 (Col5A1) and ADAMTS1, was altered by AdhVEGF-D ⌬N⌬C transduction.
To verify the findings, quantitative measurements of mRNA levels were done using qRT-PCR. Fold changes of the VEGFR-2 downstream signaling factors from GeneChip analysis and qRT-PCR are shown in Figure 3A . The activation of VEGFR-2 intracellular signaling cascade was evident 36 hours after AdhVEGF-D ⌬N⌬C transduction, but no changes in the expression level of VEGFR-2 downstream signaling factors were detected at 72 hours (data not shown). The enhanced expression of VEGF-A, stanniocalcin-1 (STC1), and NRP2 at 36 hours, as well as the downregulation of Cx37 at both time points, was also confirmed with qRT-PCR from AdhVEGF-D ⌬N⌬C -transduced and AdCMV-transduced HUVECs ( Figure  3B ). The correlation of the gene expression between qRT-PCR ( Figure 3B ) and GeneChip analysis ( Figure 3C ) was very good. The effect of the AdhVEGF-D ⌬N⌬C on induction of STC1 in cell culture was transient, and the expression of STC1 was already downregulated 72 hours posttransduction ( Figure 3B and 3C and Supplemental Table III ). Upregulation of VEGF-A, STC1, and NRP2 was also seen at the protein level in the HUVECs stimulated 48 hours with rhVEGF-D ⌬N⌬C (Figure 3D ). Western blot analysis showed a dose-dependent increase in STC1 protein expression; however, maximal upregulation for VEGF-A was achieved with 250 ng/mL and for NRP2 as soon as with 100 ng/mL of rhVEGF-D ⌬N⌬C ( Figure 3D ). The main bands recognized by monoclonal antibody against VEGF-A were migrating as 21-and 28-kDa proteins in the gel, corresponding to VEGF-A isoforms 165 and 189, respectively. Antibody against NRP2 recognized the induction of 120-and 65-kDa bands, corresponding to the size of cell surface-bound NRP2 and soluble NRP2, respectively.
For in vivo confirmations, mouse hindlimb skeletal muscles (m. caput gastrocnemius) were transduced with AdhVEGF-D ⌬N⌬C and AdCMV control virus. This is a routinely used model in which AdhVEGF-D ⌬N⌬C has been shown to have an angiogenic effect from day 4 until day 28 after gene delivery. 15 Animals were euthanized at day 5, and the transgene expression was analyzed by VEGF-D ELISA ( Supplemental Table IV ). STC1 and NRP2 were shown to be upregulated at the mRNA level in mouse skeletal muscle ( Figure 3E ). The other coreceptor for VEGFs, NRP1, was not altered by hVEGF-D ⌬N⌬C in HUVECs (GeneChip analysis and Western blot), and only minor upregulation was seen in AdhVEGF-D ⌬N⌬C -treated mouse skeletal muscle (qRT-PCR) ( Figure 3E ). In addition, upregulated expression of Col5A1 and ADAMTS1 was seen in AdhVEGF-D ⌬N⌬Ctransduced muscle samples (Supplemental Figure IV) . 
Effects of hVEGF-A 165 on STC1, NRP1, and NRP2 Expression
The next step of the study was to test how STC1, NRP1, and NRP2 respond to stimulation with hVEGF-A 165 , a wellknown activator of endothelial cells. For the experiment, HUVECs were transduced with AdhVEGF-A 165 and incubated for different times under either low-serum or highserum conditions. It was found that STC1 mRNA was strongly upregulated by AdhVEGF-A 165 under low-serum conditions ( Figure 4A ). Under high-serum conditions, significant upregulation of STC1 was also achieved; however, the response was weaker than under low-serum conditions (Figure 4A) . In addition, a significant increase in NRP1 mRNA expression was seen in AdhVEGF-A 165 -transduced HUVECs, but only under low-serum conditions ( Figure 4B) , and NRP2 mRNA level was not altered by hVEGF-A 165 in either condition ( Figure 4C ). Production of hVEGF-A 165 protein by AdhVEGF-A 165 -tranduced cells at each time point was confirmed with Western blot ( Figure 4A ).
Blocking Studies With NRP2 Small Interfering RNA and NRP Antagonist
Our gene expression studies have shown the hVEGF-D ⌬N⌬Cinduced upregulation of NRP2 in HUVECs at the mRNA level, as well as the protein level, and in mouse hindlimb skeletal muscle at the mRNA level (Figure 3 ). This is a specific response to hVEGF-D ⌬N⌬C , as hVEGF-A 165 did not alter NRP2 expression ( Figure 4C ). To study the importance of NRP2 in hVEGF-D ⌬N⌬C signaling, blocking experiments were done with small interfering RNA (siRNA) directed against NRP2. After oligotransfection, a clear decrease in NRP2 mRNA ( Figure 5A ) and protein ( Figure 5B ) expression was achieved in NRP2 siRNA-transfected HUVECs in comparison with the untreated (mock) or control siRNA-treated cells. As STC1 is known to be induced by phosphorylation of ERK1/2, 17 which is an important factor in VEGFR-2 and NRP2-mediated responses, we wanted to test the effects of NRP2 siRNA on the hVEGF-D ⌬N⌬C -induced upregulation of STC1. Interestingly, a 1.5-fold increase in STC1 mRNA was seen in control siRNA-transfected HUVECs after rhVEGF-D ⌬N⌬C stimulation (500 ng/mL), but in the presence of NRP2 siRNA, rhVEGF-D ⌬N⌬C was not able to stimulate the upregulation of STC1 any more ( Figure 5C ). The importance of NRP2 in hVEGF-D ⌬N⌬C signaling was further studied in cell survival assay. The results show that rhVEGF-D ⌬N⌬Cinduced survival of HUVECs was blocked by NRP2 siRNA; however, siRNA treatment did not have an effect on rhVEGF-A 165 -induced cell survival or on the survival of nonstimulated HUVECs ( Figure 5D ). The dose-dependent blocking pattern was also achieved when rhVEGF-D ⌬N⌬Cstimulated HUVECs were treated with different concentrations of NRP antagonist ( Figure 5E ). This peptide has been produced to inhibit the binding of hVEGF-A 165 to NRP1, but it has the same efficiency to block NRP2-mediated responses as well. 18 NRP antagonist did not have an effect on the survival of nonstimulated HUVECs ( Figure 5E ).
Discussion
Human VEGF-D ⌬N⌬C is a promising candidate for therapeutic angiogenesis. However, because of the relatively low efficiency of recombinant hVEGF-D ⌬N⌬C to activate VEGFR-2 in cell cultures, the mechanism of action has remained unclear. 16 In particular, target genes and signaling mechanisms of hVEGF-D ⌬N⌬C in endothelial cells are poorly understood. For potential clinical use of hVEGF-D ⌬N⌬C in therapeutic angiogenesis, it is essential to elucidate its functions and signaling mechanisms at the cellular level. In the present study, we found that hVEGF-D ⌬N⌬C was able to increase survival of endothelial cells and lead them toward a more proliferative and angiogenic phenotype, as already shown in earlier in vivo studies. [13] [14] [15] Unlike hVEGF-A 165 , hVEGF-D ⌬N⌬C did not induce these effects in HUVECs under low-serum conditions, only under high-serum conditions. The activation of endothelial cells by hVEGF-D ⌬N⌬C was also seen in the increased phosphorylation of VEGFR-2, Akt, and eNOS, and in the array data by upregulation of VEGFR-2 downstream signaling factors, protein biosynthesis-related genes, and solute carrier family glucose transporters ( Supplemental Table III ).
In the array study, the upregulation of 3 notable factors in vascular biology, VEGF-A, STC1, and NRP2, was found. Several other growth factors, such as epidermal growth factor, platelet derived growth factor, fibroblast growth factor-4, and placental growth factor, have been shown to upregulate VEGF-A, 4, 19, 20 but this has not previously been shown for VEGF-D. Calcium and phosphate homeostasis regulating factor STC1 is related to angiogenesis and to be upregulated by VEGF-A and hypoxia. 21, 22 In our studies, the transient upregulation of STC1 mRNA was noticed in AdhVEGF-D ⌬N⌬C -transduced HUVECs at the 36-hour time point and in mouse skeletal muscles 5 days after AdhVEGF-D ⌬N⌬C treatment. Even stronger upregulation of STC1 was observed in AdhVEGF-A 165 -transduced HUVECs. For hVEGF-D ⌬N⌬C the high-serum conditions were needed in vitro to achieve increased expression of STC1; however, for hVEGF-A 165 multi-fold higher upregulation was seen under low-serum conditions. In HUVECs, STC1 protein expression was also increased by rhVEGF-D ⌬N⌬C stimulation in a dose-dependent manner. Very little is known about the effects of STC1 on the vascular system; however, regulatory roles for inflammatory responses, endothelial permeability and apoptosis have been suggested, and it could also function as a negative feedback effector for growth factor-induced phosphorylation of ERK1/2. 17,23-25 Further experimental work is needed to clarify a possible role of the STC1 upregulation in hVEGF-D ⌬N⌬C signaling. Altered expression of VEGF-A, other growth factors, intercellular junction proteins (such as Cx37), and extracellular matrix-related genes found from gene expression data ( Supplemental Table III ) could further participate in the regulation of the angiogenic and proliferative behavior of the endothelial cells exposed to hVEGF-D ⌬N⌬C .
NRP2 is an axon guidance molecule that is normally also expressed in the vascular system on the surface of venous endothelial cells and in adult lymphatic vessels. 26, 27 It has been shown that even though hVEGF-D ⌬N⌬C does not contain the NRP2-binding sequence common in hVEGF-A 165 , hVEGF-D ⌬N⌬C can be bound to NRP2. 28 NRP2 has the capacity to form complexes with VEGFR-1, -2, and -3, and it has also been shown to enhance the effects of VEGF-A and placental growth factor in endothelial cell signaling. 4,28 -31 According to our results, NRP2 mRNA level is increased by hVEGF-D ⌬N⌬C stimulation in HUVECs, as well as in mouse hindlimb skeletal muscle. The protein level measurements from HUVEC extracts with Western blot showed upregulation of 2 distinct bands, corresponding to the cell surfacebound form (120 kDa) and the soluble form (65 kDa). The cell surface-bound form of NRP2 could have a role in enhancing the effects of hVEGF-D ⌬N⌬C in endothelial cell signaling. The soluble form of NRP2 is generated by alternative splicing from the same gene and it has been proposed to have an inhibitory effect on the function of VEGFs, although some studies suggest that soluble NRP could be sufficient to enhance the angiogenic responses. [32] [33] [34] Increased immunohistochemical staining of NRP2 has also been seen in hindlimb skeletal muscle of diabetic rabbits after AdhVEGF-D ⌬N⌬C -mediated gene transfer. 35 Even though hVEGF-D has been reported to have the capacity to bind to NRP1, 28 the Figure 5 . Blocking studies with NRP2 siRNA and NRP antagonist. siRNA directed against NRP2 decreased the expression of NRP2 at the mRNA level (A) and the protein level (B). C, Upregulation of STC1 was seen in control siRNA-transfected HUVECs stimulated with rhVEGF-D ⌬N⌬C ; however, in NRP2 siRNA-transfected cells, rhVEGF-D ⌬N⌬C was not able to stimulate the upregulation any more. The data are representative of 3 independent experiments done in triplicate (meanϮSEM), and the expression level of STC1 in nonstimulated HUVECs was set to be 1.0. In the MTS assay, NRP2 siRNA (D) and NRP antagonist (E) were both able to block rhVEGF-D ⌬N⌬C -induced survival of HUVECs. NRP2 siRNA did not have effects on the survival of rhVEGF-A 165 -stimulated HUVECs (D). The level of cellular survival of the nonstimulated HUVECs without NRP antagonist or siRNA treatment was set at 1.0, and the data are presented as meanϮSEM. For all experiments, *PϽ0.05, **PϽ0.01, ***PϽ0.005.
other known coreceptor for VEGFs, only minor changes in NRP1 expression were seen after hVEGF-D ⌬N⌬C stimulation. Different responses were achieved with hVEGF-A 165 , as AdhVEGF-A 165 transduction enhanced the expression of NRP1 and had no effects on the transcription of NRP2. Only a few factors have previously been reported to regulate the expression of NRP2. 36 -38 Among these, chicken ovalbumin upstream promoter transcription factor and growth differentiation factor-5 are, interestingly, also related to the transcriptional regulation of VEGF-D. 11, 36 The importance of NRP2 in hVEGF-D ⌬N⌬C signaling was further studied with NRP2 siRNA and NRP antagonist, which both were able to block rhVEGF-D ⌬N⌬C -induced responses in the endothelial cell survival assay. Furthermore, in the presence of NRP2 siRNA, rhVEGF-D ⌬N⌬C was not able to stimulate the upregulation of STC1 any more. rhVEGF-A 165 -induced survival of HUVECs was not altered by NRP2 siRNA.
In this study, we compared angiogenic and proliferative responses induced by hVEGF-A 165 and hVEGF-D ⌬N⌬C in endothelial cells, and we found novel target genes for hVEGF-D ⌬N⌬C . Although hVEGF-A and hVEGF-D ⌬N⌬C both bind to the VEGFR-2 and stimulate angiogenic responses at the same efficiency in vivo, their actions in vascular system are not equal. A major difference is that hVEGF-A mRNA and protein synthesis is stimulated under hypoxic conditions or by inflammatory responses, whereas hVEGF-D is constitutively expressed in normal adult arteries and atherosclerotic lesions. 3, 39 Furthermore, hVEGF-D ⌬N⌬C has slower kinetics in the stimulation of VEGFR-2 tyrosine phosphorylation, as well as its downstream signaling cascade, but the effects last longer than those induced by hVEGF-A. 16, 40 Finally, hVEGF-D ⌬N⌬C does not cause acute permeability in Miles assay, like hVEGF-A, although a chronic increase in permeability is detectable. 13, 14, 40 Thus, the role of VEGF-D in vascular biology could be related to the maintenance of vascular homeostasis, and tight regulation of the activity is needed at the protein level. This hypothesis is supported by our findings from in vitro studies, where hVEGF-D ⌬N⌬C did not function under low-serum conditions. After injury, VEGF-D is released from the vessel wall, comes into full contact with serum factors, and could therefore activate repair processes. VEGF-A, NRP2, and STC1, which were upregulated after hVEGF-D ⌬N⌬C stimulation, might thereafter amplify the effects of VEGF-D.
In conclusion, the genes found from the expression arrays help us to understand the biology of hVEGF-D ⌬N⌬C at the cellular level. In particular, the roles of STC1 and NRP2 in the effects of hVEGF-D ⌬N⌬C are important topics. Better knowledge of hVEGF-D ⌬N⌬C signaling and regulation is valuable for the development of efficient and safe AdhVEGF-D ⌬N⌬C -based therapeutic applications for cardiovascular diseases.
